BIO-TECHNE Corp Debt Securities, Available-for-sale
BIO-TECHNE Corp (TECH) had Debt Securities, Available-for-sale of $12.50 million as of 2021-06-30, per its 10-K filed 2021-08-25.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2021-08-25
- 2021-06-30: Debt Securities, Available-for-sale $12.50M.
- 2020-06-30: Debt Securities, Available-for-sale $36.40M.
- 2014-06-30: Debt Securities, Available-for-sale $11.26M.
- 2013-06-30: Debt Securities, Available-for-sale $211.88M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2021-06-30 | $12.50M 10-K · filed 2021-08-25 |
| 2020-06-30 | $36.40M 10-K · filed 2021-08-25 |
| 2014-06-30 | $11.26M 10-K · filed 2014-08-29 |
| 2013-06-30 | $211.88M 10-K · filed 2013-08-29 |
| 2012-06-30 | $201.61M 10-K · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |